Skip to main content
  • English
    • Nederlands
    • Français

Home
  • Sign In
  • Therapeutic areas
    • Cardiology
      • ASCVD
    • Dermatology
    • Hematology
      • ITP
    • Neurology
      • Multiple Sclerosis
    • Oncology
      • Breast Cancer
      • Prostate Cancer (mCRPC)
    • Ophthalmology
    • Respiratory
    • Rheumatology
  • Congresses & Events
    • Cardiology
      • BSC
      • ESC
    • Dermatology
      • EADV
    • Hematology
      • ASH
      • EHA
      • ESH
    • Neurology
      • CMSC
      • EAN
      • ECTRIMS
    • Oncology
      • ASCO
      • ESMO
      • EBCC
      • SABCS
    • Rheumatology
      • Sharing is Caring
  • Contact

Popular Search

  • improved
  • improving
  • aimovig
  • migration
  • migraine

Recent News

RLTech and Nurse Academy
Page protected by password
Netelroos - Doe the test
Search
  • Reimbursement / eHealth - Lucentis

    The reimbursement of Lucentis has to be submitted on the e-Health website:

    DUTCH

    eGezondheid

    ...

    Twitter Linkedin Facebook Pinterest Google plus
  • Beovu brochure – 3 easy steps to initiate Beovu

      Download document     .field-name-field-np4-expiry-date {display:none;} To receive by post, click on the "Add to card" button below
  • Indication - Kesimpta

    Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features 1

    Both newly diagnosed patients and patients switching from...

    Twitter Linkedin Facebook Pinterest Google plus
  • Administration & Dosing

    Twitter Linkedin Facebook Pinterest Google plus
  • Reimbursement / E-health - Kesimpta

    Kesimpta ® is reimbursed in Belgium for adult patients with clinically proven relapsing multiple sclerosis (RMS) who meet the following criteria* :

    The patient has a fast evolving, serious form of relapsing multiple sclerosis (RMS...

    Twitter Linkedin Facebook Pinterest Google plus
  • Mechanism of Action

    Kesimpta ® is a targeted and precisely delivered B-cell therapy 1,5

    B-cells play a central role in the pathogenesis of MS 4

    KESIMPTA ® (ofatumumab) is a fully human anti...

    Twitter Linkedin Facebook Pinterest Google plus
  • Patient Resources - Kesimpta

    Twitter Linkedin Facebook Pinterest Google plus
  • Guidelines - Revolade

    New ITP guidelines - a big change for your patients

    After nearly 10 years, both International (International Consensus Report / ASH Guidelines) and Belgian guidelines have finally been revised. These guidelines provide clear advice...

    Twitter Linkedin Facebook Pinterest Google plus
  • Patient Resources

    FMF patient information brochures
    Twitter Linkedin Facebook Pinterest Google plus
  • Ilaris - FMF patient brochure English

    Patient brochure | Familial Mediterranean Fever (FMF) - ENGLISH   Download document     To receive by post, click on the "Add to card" button below .field-name-field-np4-expiry-date {display:none;}
  • previous
page 

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
 of  13
  • next

Filter by specialism:

Subscribe to Novartis

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Sitemap
Cookie Settings
©2025 Novartis Belgium and Luxembourg
  • Terms of use
  • Privacy Policy
  • About cookies
This website is intended for health care professionals in Belgium and Luxembourg